Treatment-Experienced Patients
All Patients

TABLE 125: SVR GENOTYPE 2 TREATMENT-EXPERIENCED: RELATIVE RISKS AND RISK DIFFERENCE FOR ALL TREATMENT COMPARISONS — RANDOM EFFECTS MODEL

TREATMENT	REFERENCE	RR (95% CRI)	RD % (95% CRL)
SOF16 + RBV16	SOF12 + RBV12	0.86 (0.63 to 1.02)	−12.21 (−33.63 to 1.88)
SOF12 + PR12		1.07 (0.93 to 1.15)	6.57 (−6.25 to 12.59)
SOF12 + PR12	SOF16 + RBV16	1.23 (1.00 to 1.70)	18.27 (0.20 to 40.32)
Random effect model	Residual deviance	6.58 vs. 8 data points	
	Deviance information criteria	34.221	
Fixed effect model	Residual deviance	6.609 vs. 8 data points	
	Deviance information criteria	34.152	

CrI = credible interval; PR = pegylated interferon plus ribavirin; RBV = ribavirin; RD = risk difference; RR = relative risk;
SOF = sofosbuvir; SVR = sustained virologic response; vs. = versus.
Note: Please refer to Treatment Regimen Nomenclature table for description of dosages.